ANKE Bio (Group) Co., Ltd. and Hefei Alfana Biotechnology Co., Ltd. jointly developed a Class 1 new drug that received clinical approval from the Drug Administration (Drug Clinical Trial Approval Notification: 2024LP01608), with an indication for the treatment of cervical intraepithelial neoplasia. It is reported that this is the first therapeutic mRNA vaccine approved for clinical use in cervical intraepithelial neoplasia in China.
Pre-cancerous lesions and their eventual malignant changes caused by viral infections are a serious threat to people's lives and health. Globally, approximately 600 million people are infected with human papillomavirus (HPV), in addition to approximately 250 million people infected with hepatitis B virus (HBV), and 71 million people infected with hepatitis C virus (HCV). People infected with each of these viruses face a potential cancer risk. For example, approximately 30 million women are diagnosed each year with cervical intraepithelial neoplasia (CIN), an important precursor to cervical cancer. Therapeutic mRNA vaccination can efficiently clear the HPV virus while treating varying degrees of cervical intraepithelial neoplasia to achieve a cure.
These already achieved progress and results fully demonstrate the profound accumulation and innovative strength of ANKE Bio and Alfana Bio in mRNA technology platform. In the future, ANKE Bio and Alfana Bio will continue to explore new applications and directions of mRNA technology in the field of biomedicine, and with more clinical approvals and clinical trials, it is expected that they will play a more important role in the field of mRNA, and make a greater contribution to the cause of global public health.

https://mp.weixin.qq.com/s/Ndns-2-0gJBestJn1Sv3nw